Pharmacokinetics of clozapine and its metabolites in psychiatric patients: Plasma protein binding and renal clearance

British Journal of Clinical Pharmacology

Volumn 46, Issue 5, 1998, Pages 453-459

  Schaber, G ^a   Stevens, I ^a   Gaertner, H J ^a   Dietz, K ^a   Breyer Pfaff, U ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Clozapine; Clozapine N oxide; N desmethylclozapine; Plasma protein binding; Renal clearance; Tubular secretion

Indexed keywords

CLOZAPINE; CREATININE; NORCLOZAPINE; PLASMA PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; GLOMERULUS FILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; MALE; MENTAL DISEASE; MENTAL PATIENT; PH; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; URINE VOLUME;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD PROTEINS; CLOZAPINE; FEMALE; HUMANS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 0031788790     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00822.x     Document Type: Article

References (37)

1. Hippius H. The history of clozapine. Psychopharmacol 1989; 99: S3-S5.
2. Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24: 161-176.
3. Pickar D, Hsiao JK. Clozapine treatment of schizophrenia. J Am Med Ass 1995; 274: 981-983.
4. Kane JM. Drug therapy: Schizophrenia. New Engl J Med 1996; 334: 34-41.
5. Dain JG, Nicoletti J, Ballard F. Biotransformation of clozapine in humans. Drug Metab Dispos 1997; 25: 603-609.
6. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996; 16: 177-187.
7. Breyer U, Villumsen K. Measurement of plasma levels of tricyclic psychoactive drugs and their metabolites by UV reflectance photometry of thin layer chromatograms. Eur J Clin Pharmacol 1976; 9: 457-465.
8. Weigmann H, Hiemke C. Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1992; 583: 209-216.
9. Volpicelli SA, Centorrino F, Puopolo PR, et al. Determination of clozapine, norclozapine, and clozapine-N-oxide in serum by liquid chromatography. Clin Chem 1993; 39: 1656-1659.
10. Lin G, McKay G, Hubbard JW, Midha KK. Decomposition of clozapine N-oxide in the qualitative and quantitative analysis of clozapine and its metabolites. J Pharm Sci 1994; 83: 1412-1417.
11. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44: 439-446.
12. Linnet K, Olesen OV. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Metab Dispos 1997; 25: 1379-1382.
13. Tugnait M, Hawes EM, McKay G, Rettie AE, Haining RL, Midha KK. N-Oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab Dispos 1997; 25: 524-527.
14. Jann MW, Lam YWF, Chang WH. Rapid formation of clozapine in guinea-pigs and man following clozapine-N-oxide administration. Arch Int Pharmacodyn 1994; 328: 243-250.
15. Dahl ML, Llerena A, Bondesson U, Lindström L, Bertilsson L. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 1994; 37: 71-74.
16. Gauch R, Michaelis W. The metabolism of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1, 4]diazepine (clozapine) in mice, dogs and human subjects. Farmaco (edizione pratica) 1971; 26: 667-681.
17. Weigmann H, Bierbrauer J, Härtter S, Hiemke C. Automated determination of clozapine and major metabolites in serum and urine. Ther Drug Monit 1997; 19: 480-488.
18. 3- bei der Metabolisierung des Clozapins im menschlichen Körper. Arzneim-Forsch 1977; 27: 982-990.
19. Brinkschulte M, Breyer-Pfaff U. Binding of tricyclic antidepressants and perazine to human plasma. Methodology and findings in normals. Naunyn-Schmiedeberg's Arch Pharmacol 1979; 308: 1-7.
20. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994; 14: 119-125.
21. Centorrino F, Baldessarini RJ, Kando JC, et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994; 151: 123-125.
22. Olesen OV, Thomsen K, Jensen PN, et al. Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacol 1995; 117: 371-378.
23. Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhuber H. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacol 1989; 99: S38-S40.
24. Jann MW, Liu HC, Wei FC, Lin SK, Hu WH, Chang WH. Gender differences in plasma clozapine levels and its metabolites in schizophrenic patients. Hum Psychopharmacol 1977; 12: 489-495.
25. Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1997; 18: 2-9.
26. Bertilsson L, Carillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471-473.
27. Mårtensson H, Axelsson R, Nyberg G, Svensson C. Pharmacokinetic properties of the antidepressant drugs amitriptyline, clomipramine, and imipramine: a clinical study. Curr Ther Res 1984; 36: 228-238.
28. Kristensen CB. Imipramine serum protein binding in healthy subjects. Clin Pharmacol Ther 1983; 34: 689-694.
29. Midgley I, Hawkins DR, Chasseaud LF. The metabolic fate of the antidepressive agent amitriptylinoxide in man. Arzneim-Forsch 1978; 28: 1911-1916.
30. Nordin C, Almé B, Bondesson U. CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study. Psychopharmacol 1995; 122: 104-107.
31. Lieberman J, Johns C, Pollack S, et al. Biochemical effects of clozapine in cerebrospinal fluid of patients with schizophrenia. In Advances in Neuropsychiatry and Psychopharmacology, Vol. 1: Schizophrenia Research, eds Tamminga CA, Schulz SC, New York: Raven Press, 1991: 341-349.
32. Cheng YF, Lundberg T, Bondesson U, Lindström L, Gabrielsson J. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 1988; 34: 445-449.
33. Luke DR, Halstenson CE, Opsahl JA, Matzke GR. Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther 1990; 48: 503-508.
34. Becher B, Fischer W, Taneri Z, Scholz E, Müller WE, Breyer-Pfaff U. Urinary metabolites of amitriptylinoxide and amitriptyline in single-dose experiments and during continuous therapy. Psychopharmacol 1992; 106: 303-310.
35. de Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune PH. Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253: 387-394.
36. Pritchard JB, Miller DS. Renal secretion of organic cations: a multistep process. Advanced Drug Deliv Rev 1997; 25: 231-242.
37. + -glucuronide in the urine of patients treated with clozapine using electrospray mass spectrometry. Biol Mass Spectrom 1994; 23: 147-148.